Investor Presentation - First Six Months of 2021

48 Investor presentation First six months of 2021 GLP-1 sourcing is primarily from outside the class but GLP-1s are still typically used after failure on other products 100% 80% 60% 40% 20% US 'line of usage' across product classes Share of patients on OADs achieving HbA1c below 7% in major European countries 0% Metformin SU DPP-4i SGLT-2i GLP-1 1st 2nd 3rd 4th 5th Note: Data based on data from France, Germany, the UK and the USA only OAD: Oral anti-diabetic (includes but is not limited to DPP-IV, SGLT-2, metformin and sulfonylurea) Source: IQVIA Disease Analyser (France, Germany and the UK) and IQVIA LRX (USA), Jun 2018 HbA1c >7% 43% 57% Novo NordiskⓇ GLP-1 source of business (new-to-brand prescription market share) Insulin and Treatment GLP-1 naive 5% 5% Insulin 25% HbA1c <7% GLP-1 50% 11% OAD

View entire presentation